- Home
- DOLE vs XERS Comparison
DOLE vs XERS Comparison
Compare DOLE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOLE | XERS |
|---|---|---|
| Founded | 1851 | 2005 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DOLE | XERS |
|---|---|---|
| Price | $15.21 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.43 |
| AVG Volume (30 Days) | 951.2K | ★ 2.1M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $8,974,210,000.00 | $266,137,000.00 |
| Revenue This Year | $9.28 | $44.37 |
| Revenue Next Year | $1.84 | $27.87 |
| P/E Ratio | $101.68 | ★ N/A |
| Revenue Growth | 7.09 | ★ 42.05 |
| 52 Week Low | $12.20 | $3.14 |
| 52 Week High | $15.73 | $10.08 |
Technical Indicators
Market Signals| Indicator | DOLE | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 49.66 |
| Support Level | $15.32 | $6.97 |
| Resistance Level | $15.65 | $7.45 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 57.32 | 76.92 |
Price Performance
Historical ComparisonAbout DOLE Dole plc
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).